Navigation Links
Alfacell Reports Financial Results for First Quarter of Fiscal 2009
Date:12/10/2008

SOMERSET, N.J., Dec. 10 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today reported its financial results for the first quarter of fiscal 2009.

The company recorded a net loss of approximately $2.8 million, or $0.06 per basic and diluted common share, for the fiscal quarter ended Oct. 31., compared to a net loss of $2.7 million, or $0.06 per basic and diluted common share, for the first quarter of fiscal 2008. Research and development expenses increased by approximately $0.1 million and were offset by decreases in general and administrative expenses and investment income during the first quarter of fiscal 2009 as compared to the same quarter a year ago.

Cash and Liquidity

As of Oct. 31, the company had cash and cash equivalents of approximately $2.0 million, a decrease of approximately $2.7 million, compared to cash and cash equivalents of approximately $4.7 million on July 31, 2008. In addition to its cash reserves on Oct. 31, the company received proceeds of approximately $1.1 million from the sale of its state tax loss carryforwards in New Jersey in December 2008. Based on the current expected level of expenditures, the company believes that its cash reserves are sufficient to support its activities into the fourth quarter of fiscal year 2009.

Clinical/Regulatory Update

Alfacell has completed a confirmatory Phase IIIb clinical trial for ONCONASE in patients suffering from unresectable malignant mesothelioma (UMM) and reached the required number of evaluable events to conduct the formal statistical analyses required to complete the final sections of the ONCONASE(R) rolling New Drug Application (NDA). As the company has previously reported, the results of the preliminary statistical analysis of the data did not meet statistical significance for the primary endpoint of
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Alfacell to Host Fiscal First Quarter 2008 Financial Results Conference Call and Webcast
2. Sinobiopharma Reports Highlights of Third Quarter Results for Its Operating Subsidiary, Dong Ying China
3. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
4. Winner Medical Reports Fourth Quarter and Full Year Fiscal 2008 Results
5. Morpace Reports: Many Likely to Create Own Online Personal Medical Record
6. MIB Life Index Reports North American Life Insurance Activity Off 1.9% in November
7. Health Department Reports North Central Regions First Lab-Confirmed Flu Case of the Season
8. Cardium Reports on New York Citys Adoption of Therapeutic Cooling Protocols for Cardiac Arrest Patients
9. New Research Reports on Interventions that May Alter the Course of Epilepsy Diagnosis and Management
10. Cantel Medical Reports 72% Increase in Net Income on Record Sales - EPS of $0.20 vs. $0.12 for Quarter Ended October 31, 2008
11. MannKind Reports Positive Results from Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... A short, preoperative team briefing prior to cardiac ... - improves communication and reduces errors and costs, according ... Mayo researchers believe this is the first such study ... preoperative briefings on specific disruptions to surgery. Disruptions were ...
... fires, elected officials and city managers gather to prepare ... The Los Angeles County Department of Public Health today ... at your Doorstep," designed to educate elected officials and ... More than one hundred participants attended the workshop from ...
... of the recently updated 2009 editions of two ... products industry. According to Market Scope, this is ... market. New anti-VEGF therapies are successfully treating vision-threatening ... been largely untreatable. Investigational devices are promising to ...
... Systems, Inc. today announced that the Frisco Independent ... Model 615 on four occasions during the first ... President of Operations.(Logo: http://www.newscom.com/cgi-bin/prnh/20051215/OXYSURELOGO ... in its first month of implementation, only solidifies ...
... Affordable Wristbands Access to Emergency Info LAHAINA, Hawaii, ... new product originally intended for athletes, yet appealing ... simple personal safety solution. The XtremeSportsID band is ... medical alert symbol, a unique 8-digit code, and ...
... software now availableINDIANAPOLIS, May 26 ProSolv CardioVascular, ... the commercial availability of Synapse(TM) ProSolv(R) ... integration with QLAB advanced quantification software from Philips ... been designed to enhance clinical workflow, help improve ...
Cached Medicine News:Health News:Mayo Study Finds That Team Preop Briefing Improves Communication, Reduces Errors 2Health News:Mayo Study Finds That Team Preop Briefing Improves Communication, Reduces Errors 3Health News:Mayo Study Finds That Team Preop Briefing Improves Communication, Reduces Errors 4Health News:County and City Leaders Coordinate to Just Be Ready 2Health News:Market Scope Expects Retina Pharmaceutical Industry to Top $3.5 Billion by 2014 2Health News:Market Scope Expects Retina Pharmaceutical Industry to Top $3.5 Billion by 2014 3Health News:Market Scope Expects Retina Pharmaceutical Industry to Top $3.5 Billion by 2014 4Health News:Frisco ISD Treats Four Students in Medical Emergencies With OxySure(R) Model 615 2Health News:Frisco ISD Treats Four Students in Medical Emergencies With OxySure(R) Model 615 3Health News:Frisco ISD Treats Four Students in Medical Emergencies With OxySure(R) Model 615 4Health News:New Wristband May Save Lives 2Health News:New Wristband May Save Lives 3Health News:ProSolv Version 4.0.2 Makes Commercial Debut at ASE 2
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ... the "Dental Consumables Market - Global Industry ... - 2018" report to their offering. ... ) Dental consumables are products which are ... impairments, for tooth restoration and in treatment of ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading ... company, awarded several new IT value-added reseller (VAR) ... hospital organizations with IT goods and services at ... agreements, as well as value-added services such as ... New Novation agreements were awarded to ...
(Date:1/15/2014)... DUBLIN , January 15, 2014 ... that it has waived the Office of Fair Trading (OFT) ... the outstanding shares of ViroPharma Incorporated (NASDAQ: VPHM).   ... no longer conditional on OFT approval, and Shire expects to ... currently scheduled expiration time, subject to the satisfaction of all ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... 40/12.5 and 40/25 mg/day and Amlodipine +,Benazepril ... Society of,Hypertension Twenty-Second Annual Scientific Meeting, PARSIPPANY, ... data,presented today at the American Society of ... Chicago,demonstrated that the fixed-dose combination Benicar HCT,(olmesartan ...
... Calif.--(BUSINESS WIRE)--May,21, 2007 - ChemGenex Pharmaceuticals (ASX: ... clinical data relevant to the development,strategy for ... T315I mutation in Philadelphia-positive leukemias",by researchers Simona ... Italy (Haematologica Volume 92, pages 401-404) offers,insight ...
Cached Medicine Technology:Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 2Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 3Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 4Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 5Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 6Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 7Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 8Independent Publication Confirms Growing Therapeutic Challenge of,T315I Mutation in Patients with CML, Notes ChemGenex 2Independent Publication Confirms Growing Therapeutic Challenge of,T315I Mutation in Patients with CML, Notes ChemGenex 3
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
This unit is the finest standalone handswitch bipolar unit available....
...
...
Medicine Products: